Emerging drugs for Duchenne muscular dystrophy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Duchenne muscular dystrophy (DMD) is the most common, severe childhood form of muscular dystrophy. Treatment is limited to glucocorticoids that have the benefit of prolonging ambulation by approximately 2 years and preventing scoliosis. Finding a more satisfactory treatment should focus on maintaining long-term efficacy with a minimal side effect profile. AREAS COVERED: Authors discuss different therapeutic strategies that have been used in pre-clinical and clinical settings. EXPERT OPINION: Multiple treatment approaches have emerged. Most attractive are molecular-based therapies that can express the missing dystrophin protein (exon skipping or mutation suppression) or a surrogate gene product (utrophin). Other approaches include increasing the strength of muscles (myostatin inhibitors), reducing muscle fibrosis and decreasing oxidative stress. Additional targets include inhibiting NF-κB to reduce inflammation or promoting skeletal muscle blood flow and muscle contractility using phosphodiesterase inhibitors or nitric oxide (NO) donors. The potential for each of these treatment strategies to enter clinical trials is a central theme of discussion. The review emphasizes that the goal of treatment should be to find a product at least as good as glucocorticoids with a lower side effect profile or with a significant glucocorticoid sparing effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“Thismyostatin neutralizing antibodywas shown to increasemuscle mass in immunodeficient mice by approximately 30% over 3 months, similar to the biological response demonstrated for other myostatin-neutralizing antibodies [64].”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 3×
“Upregulation of utrophin holds particular advantage because of the unlikely occurrence of an immune response as seen following mini-dystrophin gene replacement [36].”
BackgroundInfluentialSelf-citationVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 2×
“, diverse truncated dystrophin proteins) result in variable severity of disease related to the ability of the truncated dystrophin peptide to correct the underlying defect [5].”
BackgroundA nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice
Wehling, M., Spencer, M. J., & Tidball, J. G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105110 · Cited by 530 · cited 1×
“Added efficacy results from the enhanced capacity of NO to improve muscle function through activation of satellite precursor cells facilitating muscle repair and regeneration [124-126].”
BackgroundA phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481 · cited 4×
“Muscle growth factors based on myostatin inhibition have not shown efficacy (MYO-29) [63] or have been encumbered by side effects that stopped the clinical trial (ACE-031; http://www/Clinicaltrials.”
BackgroundInfluentialSelf-citationClinical Uses of Melatonin: Evaluation of Human Trials
Sanchez-Barcelo, E. J., Mediavilla, M. D., Tan, D. X., & Reiter, R. J. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791233689 · Cited by 301 · cited 1×
“Considering the low side effect profile of this agent, it might be justified in considering melatonin as a candidate for a more extensive clinical trial [101].”
BackgroundRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 1×
“The potency of this agent is significantly greater than myostatin blockade alone based on studies in mice demonstrating retained activity despite a myostatinnull background [66].”
Background
Cited by
Genomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268
Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
Barrera, G., Pizzimenti, S., Daga, M., Dianzani, C., Arcaro, A., Cetrangolo, G. P., Giordano, G., Cucci, M. A., Graf, M., & Gentile, F. (2018) · Antioxidants · doi:10.3390/antiox7080102 · Cited by 326
Myostatin – The Holy Grail for Muscle, Bone, and Fat?
Buehring, B., & Binkley, N. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0160-5 · Cited by 79
Redox Characterization of Functioning Skeletal Muscle
Zuo, L., & Pannell, B. K. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00338 · Cited by 60
“For example, ROS can stimulate the production of proinflammatory cytokines including TNF-α and IL-1β through the activation of the NF-κB pathways (Malik et al., 2012).”
Background
Metadata
- Authors
- Malik, V., Rodino-Klapac, L. R., & Mendell, J. R.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-05-25
- Volume
- 17
- Issue
- 2
- Pages
- 261-277
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2132414198
- Cited by
- 97
- References
- 11
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1517/14728214.2012.691965
- The paper
- Malik, V., Rodino-Klapac, L. R., & Mendell, J. R. (2012). Emerging drugs for Duchenne muscular dystrophy. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2012.691965
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.